Nkcfo LLC Purchases Shares of 29,655 Gilead Sciences, Inc. (NASDAQ:GILD)

Nkcfo LLC acquired a new position in Gilead Sciences, Inc. (NASDAQ:GILD) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 29,655 shares of the biopharmaceutical company’s stock, valued at approximately $2,739,000. Gilead Sciences comprises about 1.2% of Nkcfo LLC’s holdings, making the stock its 19th biggest holding.

Other large investors also recently added to or reduced their stakes in the company. Bellevue Group AG boosted its holdings in Gilead Sciences by 18.2% in the 3rd quarter. Bellevue Group AG now owns 46,027 shares of the biopharmaceutical company’s stock worth $3,859,000 after buying an additional 7,093 shares during the period. Quantinno Capital Management LP grew its stake in Gilead Sciences by 149.5% during the third quarter. Quantinno Capital Management LP now owns 81,620 shares of the biopharmaceutical company’s stock valued at $6,843,000 after acquiring an additional 48,910 shares in the last quarter. McAdam LLC boosted its stake in Gilead Sciences by 16.7% during the fourth quarter. McAdam LLC now owns 25,372 shares of the biopharmaceutical company’s stock valued at $2,344,000 after buying an additional 3,627 shares during the last quarter. IRON Financial LLC purchased a new stake in shares of Gilead Sciences during the 3rd quarter valued at about $830,000. Finally, Capital Investment Advisors LLC grew its stake in shares of Gilead Sciences by 2.6% during the fourth quarter. Capital Investment Advisors LLC now owns 387,492 shares of the biopharmaceutical company’s stock valued at $35,793,000 after buying an additional 9,791 shares during the last quarter. 83.67% of the stock is currently owned by institutional investors.

Insider Transactions at Gilead Sciences

In other Gilead Sciences news, Director Jeffrey Bluestone sold 6,788 shares of the stock in a transaction on Tuesday, November 26th. The shares were sold at an average price of $91.39, for a total transaction of $620,355.32. Following the transaction, the director now directly owns 8,920 shares of the company’s stock, valued at $815,198.80. This trade represents a 43.21 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CFO Andrew D. Dickinson sold 137,676 shares of the business’s stock in a transaction dated Wednesday, February 12th. The stock was sold at an average price of $102.22, for a total transaction of $14,073,240.72. Following the sale, the chief financial officer now directly owns 171,223 shares of the company’s stock, valued at $17,502,415.06. This represents a 44.57 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 710,500 shares of company stock valued at $67,684,956 in the last ninety days. 0.16% of the stock is currently owned by corporate insiders.

Gilead Sciences Stock Down 1.8 %

Shares of GILD opened at $104.08 on Friday. The company has a market capitalization of $129.71 billion, a price-to-earnings ratio of 1,156.44, a PEG ratio of 1.25 and a beta of 0.18. Gilead Sciences, Inc. has a 52 week low of $62.07 and a 52 week high of $106.69. The stock’s 50-day moving average price is $93.87 and its 200-day moving average price is $87.55. The company has a quick ratio of 1.10, a current ratio of 1.26 and a debt-to-equity ratio of 1.24.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings data on Tuesday, February 11th. The biopharmaceutical company reported $1.90 EPS for the quarter, topping the consensus estimate of $1.67 by $0.23. Gilead Sciences had a return on equity of 29.00% and a net margin of 0.45%. On average, sell-side analysts predict that Gilead Sciences, Inc. will post 4.35 EPS for the current year.

Gilead Sciences Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, March 28th. Shareholders of record on Friday, March 14th will be given a $0.79 dividend. The ex-dividend date of this dividend is Friday, March 14th. This represents a $3.16 dividend on an annualized basis and a dividend yield of 3.04%. This is an increase from Gilead Sciences’s previous quarterly dividend of $0.77. Gilead Sciences’s dividend payout ratio is 3,422.22%.

Wall Street Analysts Forecast Growth

A number of equities analysts recently issued reports on the company. Wolfe Research began coverage on Gilead Sciences in a report on Friday, November 15th. They set an “outperform” rating and a $110.00 price objective for the company. Royal Bank of Canada upped their price target on shares of Gilead Sciences from $84.00 to $90.00 and gave the stock a “sector perform” rating in a report on Wednesday. Maxim Group lowered shares of Gilead Sciences from a “buy” rating to a “hold” rating in a report on Friday, November 8th. Citigroup began coverage on shares of Gilead Sciences in a research note on Thursday, November 14th. They issued a “buy” rating and a $125.00 target price on the stock. Finally, BMO Capital Markets boosted their price target on Gilead Sciences from $110.00 to $115.00 and gave the company an “outperform” rating in a report on Wednesday. Eleven investment analysts have rated the stock with a hold rating, fourteen have given a buy rating and four have given a strong buy rating to the company. According to MarketBeat, Gilead Sciences currently has a consensus rating of “Moderate Buy” and a consensus target price of $101.33.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.